CD9 and neoplasm: This could be potentially driven by the hematopoietic lineage-specific difference in the composition of CD9 binding partners within the tetraspanin web, a well-recognized phenomenon in solid cancers to determine its oncogenic versus tumor suppressive role that deserves further biological studies in leukemias [12, 13].